EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

O2L-001, an innovative thrombolytic to evacuate intracerebral haematoma

Audrey M Thiebaut iD, Estelle R Louet, Mélina Ianszen, Marie-Julie Guichard, Daniel F Hanley, Christophe Gaudin, Jérôme Parcq

Brain · 02.11.2023 · 146 (11) · 4690-4701

DOI: 10.1093/brain/awad237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 14.07.2023. Verfasst von Audrey M Thiebaut und 6 weiteren Autor:innen. Beteiligte Einrichtung: Op2Lysis SAS, GIP Cyceron, 14000 Caen, France. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Fibrinolysin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Op2Lysis SAS, ANRT, Bpifrance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intracerebral haemorrhage is an unmet medical need affecting more than 3 million people worldwide every year and leading to the formation of an intracerebral haematoma. Updated guidelines (2022) for the management of intracerebral haemorrhage patients recognize that minimally invasive approaches for the evacuation of supratentorial intracerebral haemorrhage have demonstrated reductions in mortality compared with medical management alone. However, improvement of functional outcome with a procedure involving thrombolytic therapy was neutral in the last large phase 3 clinical trial and requires a more effective and safer thrombolytic agent than those currently available. Here, we demonstrate that O2L-001 allows for the extended release of W253R/R275S recombinant tissue-type plasminogen activator (rtPA). A new rtPA variant, called optimized tPA (OptPA), offers improved efficacy for haematoma evacuation as well as improved safety. OptPA was produced in a Chinese hamster ovary cell line before purification, nanoprecipitation using the NANOp2Lysis® technological platform followed by suspension in a solution of 17% poloxamer 407 to obtain O2L-001. Plasmin generation assays were performed to demonstrate O2L-001 safety. Ex vivo haematoma models using human blood were used to demonstrate O2L-001 thrombolysis properties and efficacy. For the best translational significance, a clinical sized haematoma was used to ensure catheter placement and to allow administration of the thrombolytic agent into the core of the haematoma via a minimally invasive procedure. The capacity of OptPA to convert plasminogen into plasmin is strongly decreased compared to rtPA, thereby reducing potential bleeding events. However, a clot lysis assay showed that OptPA had the same fibrinolytic activity as rtPA. We demonstrated that long-term exposure to a thrombolytic agent was essential to achieve high thrombolysis efficacy. Indeed, 24 h continuous exposure to 0.1 µg/ml rtPA had similar efficacy than repeated short exposure to 30 µg/ml rtPA. This finding led to the development of O2L-001, allowing the extended release of OptPA in the first 6 h following injection. An ex vivo model using human blood was used to demonstrate O2L-001 efficacy. Interestingly, unlike rtPA, O2L-001 was able to induce the complete lysis of the 5 ml haematoma. In clinical sized haematomas (obtained from 30 ml of human blood), a single injection of O2L-001 at 1 mg/ml into the core of the haematoma led to a 44% increase in thrombolysis compared to rtPA. Taken together, these results demonstrate that O2L-001 provides new hope for haematoma evacuation and the treatment of patients with intracerebral haemorrhage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibrinolytic AgentsFibrinolysinAnimalsCricetinaeHumansCHO CellsCricetulusTissue Plasminogen ActivatorCerebral HemorrhageThrombolytic TherapyHematoma

Stichwörter der Autor:innen

haematoma modelhaemorrhagic strokeintracerebral haematomaplasminogen activatorthrombolysis

Substanzen

Fibrinolytic AgentsFibrinolysinTissue Plasminogen Activator

Autor:innen und Institutionen

  • Op2Lysis SAS, GIP Cyceron, 14000 Caen, France.
  • Normandie Univ, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron, Institut Blood and Brain @ Caen-Normandie (BB@C), 14000 Caen, France.
  • The Johns Hopkins Medical Institutions, BIOS, Baltimore, MD 21202, USA.

ORCID-Profile: Audrey M Thiebaut

Förderung

  • Op2Lysis SAS
  • ANRT
  • Bpifrance
  • Ministry of Higher Education, Research and Innovation

Zitieren

APA

Thiebaut, A. M., Louet, E. R., Ianszen, M., Guichard, M. J., Hanley, D. F., Gaudin, C., & Parcq, J. (2023). O2L-001, an innovative thrombolytic to evacuate intracerebral haematoma. Brain, 146(11), 4690-4701. https://doi.org/10.1093/brain/awad237

Vancouver

Thiebaut AM, Louet ER, Ianszen M, Guichard MJ, Hanley DF, Gaudin C, et al. O2L-001, an innovative thrombolytic to evacuate intracerebral haematoma. Brain. 2023;146(11):4690-4701. doi:10.1093/brain/awad237

BibTeX
@article{Thiebaut2023,
  author = {Thiebaut, Audrey M and Louet, Estelle R and Ianszen, Mélina and Guichard, Marie-Julie and Hanley, Daniel F and Gaudin, Christophe and Parcq, Jérôme},
  title = {O2L-001, an innovative thrombolytic to evacuate intracerebral haematoma},
  journal = {Brain},
  year = {2023},
  volume = {146},
  number = {11},
  pages = {4690--4701},
  doi = {10.1093/brain/awad237}
}
Kostenlos starten →